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Core binding factor acute myeloid leukemia (AML) comprises twosubtypes with distinct cytogenetic abnormalities of eithert(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). Since long-
term response to chemotherapy in these leukemias is relatively good,
allogeneic hematopoietic stem cell transplantation is considered in
patients who relapse and achieve second complete remission. To evalu-
ate the outcomes of allogeneic transplantation in this indication, we
studied 631 patients reported to the European Society for Blood and
Marrow Transplantation Registry between the years 2000 and 2014.
Leukemia-free survival probabilities at two and five years were 59.1%
and 54.1%, while overall survival probabilities were 65% and 58.2%,
respectively. The incidence of relapse and risk of non-relapse mortality at
the same time points were 19.8% and 22.5% for relapse and 20.9% and
23.3% for non-relapse mortality, respectively. The most important
adverse factors influencing leukemia-free and overall survival were:
leukemia with t(8;21), presence of three or more additional chromosomal
abnormalities, and Karnofsky performance score <80. Relapse risk was
increased in t(8;21) leukemia and associated with additional cytogenetic
abnormalities as well as reduced intensity conditioning. Measurable
residual disease in molecular evaluation before transplantation was asso-
ciated with increased risk of relapse and inferior leukemia-free survival.
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ABSTRACT
Introduction
Core binding factor (CBF) leukemia represents up to 12% of all newly diagnosed
adult acute myeloid leukemia (AML).1 Chromosomal markers of CBF AML include
t(8;21)(q22;q22) and inv(16)(p13q22) or less frequently t(16;16)(p13;q22), further
described jointly as inv(16). As a result of chromosomal abnormalities, fusion tran-
scripts RUNX1-RUNX1T1 in t(8; 21) and CBFB-MYH11 in inv(16) emerge. The tran-
scripts represent molecular attributes of CBF AML and are
driver mutations for leukemogenesis. They disrupt normal
hematopoiesis dependent on core binding factor subunit α
(RUNX1) and β (CBFB) by silencing tumor suppressor
genes leading to neoplastic transformation.2
Accompanying secondary gene mutations (mutations of
NRAS, KIT, NF1, FLT3, KRAS, ASXL1&2), additional cyto-
genetic abnormalities, and clinical features at diagnosis
(age, white blood cell and blast counts, extramedullary
involvement) affect treatment outcomes, but general prog-
nosis in CBF AML remains favorable.3,4 Indeed, current
induction chemotherapy standards lead to a complete
remission (CR) rate of 87-89%, involving a high propor-
tion of younger patients.5,6 Repeated high or intermediate-
dose cytarabine consolidation provides long-term disease
control in a large proportion of patients. Conventional
chemotherapy results in long-term survival in 53-64% of
patients.  The major reason for treatment failure in CBF
AML is relapse, reported in 30-50% of patients.7,8 Given
the  relatively favorable results of chemotherapy, patients
with CBF leukemia are not usually candidates for allo-
geneic hematopoietic stem cell transplantation (HSCT) in
first CR (CR1). However, CBF AML is a heterogeneous
group of malignancies. Several variables, including type of
CBF subunit involved, age, additional molecular or cytoge-
netic abnormalities, and dynamics of measurable residual
disease (MRD) are known to influence the outcomes and
contribute to disease recurrence.7-11 HSCT is recognized as
a standard procedure in patients who relapse and subse-
quently achieve CR2.4,12 To evaluate the results of HSCT in
CBF AML patients in CR2, we decided to perform a retro-
spective study using registry data from the Acute
Leukemia Working Party (ALWP) of the European Society
for Blood and Marrow Transplantation (EBMT). The
EBMT is a non-profit, scientific society representing more
than 600 transplant centers, mainly in Europe. Member
centers are required to report all consecutive stem cell
transplantations and follow ups once a year. Data are
entered, managed, and maintained in a central database
with internet access; each EBMT center is represented in
this database. Audits are routinely performed to deter-
mine accuracy of data.  Before transplantation, patients or
legal guardians provide informed consent authorizing the
use of their anonymized personal information for research
purposes.
Methods
Patients and data selection
The study was approved by the ALWP Institutional Review
Board and included all adult patients undergoing HSCT in the peri-
od from the year 2000 to 2014 reported to the EBMT. The centers
were asked by survey to provide data on all patients with t(8;21)
or inv(16) to verify the cytogenetic aberrations and to update the
transplantation outcomes using designated clinical forms. The
patients had to have de novo CBF AML, with classical cytogenetics
confirmation of t(8;21) or inv(16) at initial diagnosis, undergoing
HSCT in hematologic CR2, defined as less than 5% blasts in the
bone marrow (BM) and absence of extramedullary involvement,
and regardless of current peripheral blood (PB) counts (i.e. bona fide
CR or CR with incomplete hematologic recovery). All patients
received BM or PB transplantation  (BMT, PBSCT) from matched
sibling (MSD) or unrelated donors (UD) after myeloablative
(MAC) or reduced intensity (RIC) conditioning, as defined by the
EBMT criteria.13 The variables selected to assess outcomes were:
age, type of AML, white blood cell count, presence of
extramedullary involvement at diagnosis, additional cytogenetic
abnormalities, time from diagnosis to CR1, duration of CR1, time
from diagnosis and from CR2 to transplantation, molecular remis-
sion status at transplantation, Karnofsky performance score (KPS)
at transplantation, sex matching of patients and donors,
cytomegalovirus (CMV) serological status of patients and donors,
year of transplantation, type of the donor, source of stem cells,
conditioning intensity, and in vivo T-cell depletion.
End points and statistical analysis
The primary end point was leukemia-free survival (LFS).
Secondary end points were: overall survival (OS), relapse inci-
dence (RI), non-relapse mortality (NRM), graft-versus-host disease-
free and leukemia-free survival (GRFS), as well as acute and chron-
ic graft-versus-host disease (aGvHD and cGvHD). LFS was defined
as survival without any symptoms of disease recurrence. OS was
defined as probability of survival from transplantation to the last
follow up. Relapse was defined as presence of  >5% blasts in the
BM or extramedullary disease after transplantation. NRM was
defined as mortality from any cause not related to disease recur-
rence and GRFS was defined as survival without leukemia,
aGvHD grade III-IV or extensive cGvHD.14 Minimal residual dis-
ease (MRD) was measured in the BM during the interval between
last chemotherapy and transplantation. Real-time quantitative
polymerase chain reaction (RT-qPCR) was used for RUNX1-
RUNX1T1 and CBFB-MYH11 quantification. MRD results were
reported by the centers as absent (MRDneg) or present (MRDpos)
in line with their local guidelines. Acute GvHD was graded
according to Glucksberg criteria.15 Surviving patients were cen-
sored at last follow up. Probabilities of LFS, OS, and GRFS were
calculated using Kaplan-Meier estimates. Cumulative incidence
functions (CIF) were used to determine RI and NRM in a compet-
ing risk setting with each other. Univariate analyses were per-
formed using Gray’s test for CIF and the log-rank test for LFS and
OS. For all univariate analyses, continuous variables were catego-
rized and the median was used as cut-off point. Associations of
patient and transplantation characteristics with outcomes were
evaluated in multivariate analysis using Cox proportional hazards
model. Multivariate models were built by using stepwise selection
procedure. Results were expressed as the hazard ratio (HR) with
95% Confidence Interval (CI). All tests were two-sided. The type-
1 error rate was fixed at 0.05 for determination of factors associat-
ed with time to event outcomes. Statistical analyses were per-
formed with SPSS 24 (SPSS Inc. /IBM, Armonk, NY, USA) and R
1.3.0 (R Development Core Team, Vienna, Austria) software pack-
ages.
Results
The detailed characteristics of the 631 patients from 181
transplant centers who met the study inclusion criteria are
shown in Table 1. Three hundred and sixty-six patients
(58%) harbored inv(16) and 265 (42%) t(8;21). The two
groups were compared for essential patient and transplant
characteristics (Online Supplementary Table S1). The differ-
ences included: sex of the patients [with more males in the
t(8;21) group], time from diagnosis to transplantation
[which was longer in the t(8;21) group], and time from
diagnosis to CR1 [which was also longer in the t(8;21)
group]. Altogether there were 361 (57%) males and 270
(43%) females. Median age at transplantation was 41.7
years [range 18-73, interquartile range (IQR) 31.3-51.2],
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and the median year of transplantation was 2010. Nearly
half of the procedures were performed between the years
2010 and 2014. Additional analysis of transplantation
intervals 2000-2005, 2006-2009, and 2010-2014 periods
did not reveal any significant differences in outcomes.
Twenty-one percent of patients had additional cytogenet-
ic aberrations detected at diagnosis. The most frequent of
them was presence of three or more abnormalities
(32.5%). There was a low frequency of reports of accom-
panying molecular abnormalities (cKIT mutations, FLT3-
ITD, NRAS mutations and KRAS mutations) which pre-
cluded subset evaluation. The most frequent available
information on co-mutation pattern was FLT3-ITD, which
was reported in 26 patients, with a similar distribution
between the  inv(16) and the t(8;21) groups (14 and 12
patients, respectively). Three hundred and forty-three
(73.3%)  patients were MRDneg, while 125 (26.7%) were
MRDpos before transplantation. There was a trend for
higher frequency of MRDpos patients in the t(8;21) com-
pared to the inv(16) subgroup (P=0.06) (Online
Supplementary Table S1). Further analysis showed signifi-
cant differences in terms of LFS, OS, and relapse in favor
of inv(16) compared to t(8;21) AML in MRDneg but not
MRDpos patients (Online Supplementary Table S2).
Engraftment was achieved in 619 (98.7%) patients.
Leukemia-free survival
The 2- and 5-year probability of LFS was 59.1%
(95%CI: 55.2-63.1) and 54.1% (95%CI: 50-58.2), respec-
tively. In univariate analysis, LFS was significantly higher
for patients with inv(16) compared to patients with t(8;21)
(63.8% vs. 52.5%, P=0.003) (Figure 1A). Presence of three
or more additional cytogenetic abnormalities at diagnosis
resulted in worse LFS (37.5% vs. 60.4%, P=0.002). For
MRDpos patients, the probability of LFS was 49% com-
pared to 61.6% for patients who were MRDneg (P=0.046)
(Figure 2A). Performance status was also an important fac-
tor, with 2-year LFS probability of 59.9% for patients with
KPS ≥80 versus 37.5% for those with KPS <80 (P=0.003).
The results of the univariate analysis are provided in
Online Supplementary Table S3. In multivariate analysis, the
type of CBF AML [t (8;21) versus inv(16)] was an inde-
pendent factor for LFS (HR=1.40, 95%CI: 1.05-1.86,
P=0.022) as was presence of three or more additional cyto-
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Table 1. Patients’ and transplant characteristics. Percentage values in
parentheses refer to reported data.
Number of patients                                                                631 
Median follow up, months (range)                                         59.6 (0.9 - 201)
Median year of transplantation (range)                             2010 (2000-2014)
Type of AML                                                                                                
inv(16)                                                                                         366(58%)
t(8;21)                                                                                         265(42%)
Median age at transplantation, years (range; IQR)     41.7 (18 -73; 31.3-51.2)
Median CR1 duration, days (range; IQR)                        318 (6-2380; 246-474)
Median time from diagnosis to transplantation,          17 (3.5-222.9; 14-22.5)
months (range; IQR)
Sex                                                                                                                
Male                                                                                                361(57.2%)
Female                                                                                           270(42.8%)
Donors                                                                                                         
Matched siblings                                                                         264(42%)
Unrelated                                                                                      367(58%)
Additional chromosomal abnormalities                                              
No abnormality reported                                                            497(79%)
3 or more abnormalities                                                               32(5%)
Abn5                                                                                                   2(0.3%)
Abn7                                                                                                  10(1.6%)
Del 9                                                                                                   5(0.8%)
Del X or Y                                                                                         18(2.9%)
Trisomy 22                                                                                        9(1.4%)
Trisomy 8                                                                                         10(1.6%)
Hyperdiploidy                                                                                  4(0.6%)
Hypodiploidy                                                                                    7(1.1%)
Undefined/other abnormalities                                                  34(5.39)
Molecular remission at transplantation                                              
Molecular CR                                                                               343(73.3%)
No molecular CR                                                                        125(26.7%)
Missing                                                                                                 163
Karnofsky performance score                                                               
<80                                                                                                    16(2.8%)
≥80                                                                                                  559(97.2%)
Missing                                                                                                   56
Conditioning intensity                                                                              
Myeloablative                                                                                424(67.5%)
Reduced intensity                                                                       204(32.5%)
Missing                                                                                                    3
Source of stem cells                                                                                
Bone marrow                                                                                 117(18.5%)
Peripheral blood                                                                           514(81.5%)
GvHD prophylaxis                                                                                      
CsA based                                                                                      584(92.6%)
Tacrolimus based                                                                           26(4%)
PTCY                                                                                                    6(1%)
Other                                                                                                10(1.6%)
Missing                                                                                              5(0.8%)
In vivo T-cell depletion                                                                            
Yes                                                                                                  325(51.8%)
No                                                                                                    302(48.2%)
Missing                                                                                                    4
Donor sex                                                                                                   
Male                                                                                                369(59.4%)
Female                                                                                           252(40.6%)
Missing                                                                                                   10
Female to male transplantation                                                  133(21.2%)
CMV serology                                                                                             
Patient CMV IgG positive                                                            387(63%)
Donor CMV IgG positive                                                            305(49.9%)
Engraftment                                                                                                
Yes                                                                                                  619(98.7%)
No                                                                                                       8(1.3%)
Missing                                                                                                    4
aGvHD grade II-IV                                                                                     
Yes                                                                                                  171(27.9%)
No                                                                                                    443(72.1%)
Missing                                                                                                   17
cGvHD                                                                                                          
Yes                                                                                                  279(46.7%)
No                                                                                                    318(53.3%)
Missing                                                                                                   34
AML: acute myeloid leukemia; IQR: interquartile range; CR1: first complete remission;
abn 5: abnormalities of chromosome 5; abn 7: abnormalities of chromosome 7; del 9
complete or partial deletion of chromosome 9; del X or Y, deletion of chromosome X
or Y; trisomy 22: trisomy of chromosome 22; trisomy 8: trisomy of chromosome 8; CR:
complete remission; GvHD: graft-versus-host disease; CsA: cyclosporine A; PTCY: post-
transplant cyclophosphamide; CMV IgG: cytomegalovirus-specific immunoglobulin G
antibody; aGvHD: acute graft-versus-host disease; cGvHD: chronic graft-versus-host dis-
ease.
continued in next column
genetic abnormalities (HR=2.09, 95%CI: 1.27-3.42,
P=0.004), and KPS ≥80 (HR=0.32; 95%CI: 0.14-0.73,
P=0.32). In multivariate analysis, MRDneg was not an
independent prognostic factor for LFS (HR=0.76; 95%CI:
0.55-1.03, P=0.08) (Table 2).
Overall survival
Two- and 5-year OS probability for the whole group
was 65% (95%CI: 61.2-68.9) and 58.2% (95%CI: 54.1-
62.3), respectively. In univariate analysis, patients with
t(8;21) AML had a lower probability of OS compared to
those with inv(16) (57% vs. 70.5%, P=0.0003) (Figure 1B).
Three or more additional cytogenetic abnormalities was
associated with lower OS (49.6% vs. 65.9%, P=0.013).
Performance status at transplantation influenced OS. OS
of patients with KPS≥80 was 66.1% versus 37.5% in those
with KPS<80 (P=0.003) (Online Supplementary Table S3).
MRDneg was not significantly associated with OS (Figure
2B). Multivariate analysis confirmed the findings of the
univariate analysis. AML with t(8; 21), additional cytoge-
netic abnormalities, and KPS <80 were the three inde-
pendent prognostic factors for significantly worse OS
with HR 1.76 (95%CI: 1.35-2.28, P=0.00002), HR 1.68
(95%CI: 1.03-2.72, P=0.037), and HR 0.36 for KPS ≥80
(95%CI: 0.19-0.68, P=0.002), respectively (Table 2). In
multivariate analysis, MRD status was not an independent
prognostic factor for OS (59.9%; 95%CI: 50.8-68.9 vs.
65.8%; 95%CI: 60.7-71, P=0.47). Age at HSCT (below or
above the median) did not affect OS (66.5%; 95%CI: 61.1-
71 vs. 63.6%; 95%CI: 58.1-69, P=0.39). 
Relapse incidence
The risk of relapse at two and at five years was estimat-
ed at 19.8% (95%CI: 16.7-23.1) and 22.5%  (95%CI: 19.2-
26). In patients with t (8; 21), the risk of relapse at two
years was significantly higher: 25.8% versus 15.6% in
those with inv (16) (P=0.009) (Figure 1C). The risk of
relapse was higher in patients with three or more addi-
tional chromosomal aberrations (34.4% vs. 19%, P=0.03).
In the whole cohort, MRDneg patients had a significantly
decreased risk of relapse compared to MRDpos patients
(16.2% vs. 29.3%, P=0.003) (Figure 2C). In patients with
CR1 shorter than the median (318 days), the risk of relapse
after transplantation was higher (26.4% vs. 13%, P<
0.001). Time from diagnosis to transplantation was also
significant. In patients receiving HSCT within a shorter
time than the median (17 months from diagnosis), the risk
of relapse was higher (26.4% vs. 13.1%, P<0.001).
Conditioning intensity was also important. Patients
receiving RIC experienced more leukemia relapses com-
pared to those receiving MAC (25.9% vs. 17%, P=0.002).
Finally, in vivo T-cell depletion led to more recurrences
(22.6% vs. 16.7% in patients transplanted without T-cell
depletion (P=0.02) (Online Supplementary Table S3). In mul-
tivariate analysis, t(8; 21) versus inv(16), presence of three
or more additional chromosomal abnormalities, time from
diagnosis to transplantation (> vs. ≤ median), MRDneg,
and RIC were independent significant prognostic factors
for relapse. The corresponding HR values for those factors
were 1.89 (95%CI; 1.26-2.84, P=0.002), 2.31 (95%CI:
1.23-4.4, P=0.011), 0.97 (95%CI: 0.94-0.99, P=0.023), 0.65
(95%CI: 0.42-0.99, P=0.043), and 1.64 (95%CI: 1.09-2.47,
P=0.017), respectively. In vivo T-cell depletion was not con-
firmed to be an independent risk factor for relapse in mul-
tivariate analysis (Table 2).
Non-relapse mortality
The 2- and 5-year incidence of NRM was 20.9%
(95%CI: 17.7-24.2) and 23.3% (95%CI: 19.9-26.8), respec-
tively. In univariate analysis, KPS <80 versus ≥80 was
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Table 2. Multivariate analysis using Cox proportional hazards model. Variables with P< 0.15 in univariate analysis were included in the model.
                                                                                                                                         P                                   HR                                 95% CI 
LFS                              t(8;21) vs. inv(16)                                                                                               0.022                                      1.40                                       1.05-1.86 
                                  ≥3 chromosomal abnormalities vs. no                                                          0.004                                      2.09                                       1.27-3.42 
                                  Molecular MRDneg vs. MRDpos                                                                      0.080                                      0.76                                       0.55-1.03 
                                  KPS ≥ 80 vs. < 80                                                                                                 0.006                                      0.32                                       0.14-0.73 
OS                               t(8;21) vs. inv(16)                                                                                             0.00002                                    1.76                                       1.35-2.28 
                                  ≥3 chromosomal abnormalities vs. no                                                          0.037                                      1.68                                       1.03-2.72 
                                  KPS ≥ 80 vs. < 80                                                                                                 0.002                                      0.36                                       0.19-0.68 
RI                                t(8;21) vs. inv(16)                                                                                               0.002                                      1.89                                       1.26-2.84 
                                  ≥3 chromosomal abnormalities vs. no                                                          0.011                                      2.31                                       1.23-4.40 
                                  Time from diagnosis to transplantation (>median>)                              0.023                                      0.97                                       0.94-0.99 
                                  RIC vs. MAC                                                                                                          0.017                                      1.64                                       1.09-2.47 
                                  Molecular MRDneg vs. MRDpos                                                                      0.043                                      0.65                                       0.42-0.99 
NRM                           KPS ≥ 80 vs. < 80                                                                                                 0.001                                      0.29                                       0.14-0.59 
GRFS                          Molecular MRDneg vs.MRDpos                                                                      0.054                                      0.77                                       0.60-1.00 
                                  ≥3 chromosomal abnormalities vs. no                                                          0.031                                      1.61                                       1.04-2.47 
                                  In vivo TCD vs. no                                                                                               0.027                                      0.76                                       0.60-0.97 
                                  Donor CMV IgG negative vs. positive                                                             0.058                                      0.79                                       0.99-1.61 
aGvHD II-IV               RIC vs. MAC                                                                                                          0.011                                      0.64                                       0.45-0.90 
cGvHD                        In vivo TCD vs. no                                                                                               <10-5                                     0.56                                       0.43-0.72 
                                  Donor CMV IgG positive vs. negative                                                              0.004                                      1.45                                       1.13-1.87 
                                  PBSCT vs. BMT                                                                                                    0.003                                      1.72                                       1.20-2.46 
LFS: leukemia-free survival; MRDneg: minimal residual disease negative; MRDpos: minimal residual disease positive; KPS: Karnofsky performance score; OS: overall survival; RI:
relapse incidence; RIC: reduced intensity conditioning; MAC: myeloablative conditioning; NRM: non-relapse mortality; GRFS: graft-versus-host disease-free, relapse-free survival;
CMV IgG: cytomegalovirus-specific immunoglobulin G antibody; TCD: T-cell depletion; aGvHD II-IV: acute graft-versus-host disease, grades II to IV;cGVHD: chronic graft-versus-
host disease; PBSCT: peripheral blood stem cell transplantation; BMT: bone marrow transplantation.
strongly associated with NRM (50% vs. 19.8%, P=0.002).
Patients in whom CR1 duration was shorter than the
median, or those who were transplanted at a shorter time
from diagnosis than the median, experienced decreased
NRM (17.1% vs. 25.8%, P=0.007 and 18% vs. 24%,
P=0.01, respectively) (Online Supplementary Table S3). In
multivariate analysis, only performance status was an
independent risk factor for NRM; HR 0.29 (95%CI: 0.14-
0.59, P=0.001) for patients with KPS ≥80 versus those with
KPS <80 (Table 2).
Graft-versus-host disease-free and leukemia-free 
survival
The 2- and 5-year probability of GRFS was 40.2%
(95%CI: 36.2-44.2) and 34.6% (95% CI: 30.6-38.6),
respectively. The 2-year probability of GRFS for patients
with inv (16) was higher than for those with t(8; 21)
(44.1%  vs. 34.7%, P=0.049). Presence of three or more
additional chromosomal aberrations was significantly
associated with worse GRFS (20% vs. 41.3%, P=0.01).
Patients who were MRDneg before transplantation had a
higher probability of GRFS (42.9% vs. 29.2%, P=0.02).
Similarly, those who received in vivo T-cell depletion had
a higher GRFS (46.1% vs. 33.9%, P=0.004). Finally, there
was a trend for better GRFS in patients transplanted from
CMV seronegative versus seropositive donors (41.8% vs.
38.4%, P=0.07) (Online Supplementary Table S3). In multi-
variate analysis, factors independently associated with
GRFS were three or more cytogenetic abnormalities and
in vivo T-cell depletion (HR 1.61; 95%CI: 1.04-2.47, P=0.03
and HR 0.76; 95%CI: 0.6-0.97, P=0.027, respectively).
Transplantation from CMV negative donors and MRDneg
status were associated with a trend for better GRFS
(HR0.79; 95%CI: 0.62-1, P=0.058 and HR 0.77; 95%CI:
0.6-1.0, P=0.054, respectively) (Table 2).
Graft-versus-host disease
The incidence of aGvHD grades II to IV and III-IV was
28% (95%CI: 24.5-31.6) and 9.5% (95%CI: 7.3-12),
respectively. In univariate analysis, transplantation from
MSD compared to UD was associated with lower inci-
dence of grade II-IV aGvHD (24.1% vs.  30.8%, P=0.049).
Grade II-IV aGvHD was higher in patients transplanted
with BM vs.  PB grafts (36% vs.  26.1%, P=0.04). MAC in
comparison to RIC was associated with increased inci-
dence of aGvHD grade II-IV (30.8% vs. 21.6%, P=0.01). In
vivo T-cell depletion reduced grade II-IV (23.6% vs.
32.7%, P=0.01) and grade III-IV (5.7% vs. 13.6%,
P=0.009) aGVHD incidence (Online Supplementary Table
S3). In multivariate analysis, only intensity of condition-
ing regimen (RIC vs.  MAC) was an independent prognos-
tic factor for aGvHD grade II-IV: HR 0.64 (95%CI: 0.45-
0.9), P=0.011 (Table 2).
The incidence of cGvHD at two and five years post
transplant was 46.7% (95%CI: 42.5-50.8) and 48.4%
(95%CI: 44-52.4), respectively. Transplantation from
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Figure 1. Leukemia-free survival (LFS), overall survival (OS), and relapse inci-
dence (RI) in patients with core-binding factor acute myeloid leukemia (CBF
AML) transplanted in second complete remission for patients with inv(16) ver-
sus t(8;21). 2-year probability of LFS: 63.8% (95% CI: 58.8-68.8) vs. 52.5%
(95% CI: 46.2-58.8), P=0.003. 2-year probability of OS: 70.5% (95% CI: 65.8-
75.3) vs. 57% (95% CI: 50.7-63.2), P=0.0003. 2-year risk of relapse: 15.6%
(95% CI: 12-19.6) vs. 25.8% (95% CI: 20.5-31.4), P=0.009.
female versus male donors was associated with increased
risk of cGvHD (52.1% vs. 43.4%, P=0.01); the same was
true for female to male transplantations versus other com-
binations (55.2% vs.  44.5%, P=0.03). Transplantation
from CMV positive versus CMV negative donors also cor-
related with increased risk of cGvHD (53.2% vs. 40.5%,
P=0.002). BM versus PB grafts resulted in lower incidence
of cGVHD (37.1% vs. 49.1%, P=0.04). In vivo T-cell deple-
tion decreased risk of cGVHD (37.7% vs. 55.9%, P<0.001)
(Online Supplementary Table S3). In multivariate analysis, in
vivo T-cell depletion was an independent factor for
decreased risk of cGvHD (HR=0.56; 95%CI: 0.43-0.72,
P<0.001), while PBSCT and CMV donor seropositivity
were associated with increased risk of cGVHD (HR=1.72;
95%CI; 1.2-2.46, P=0.003 and HR=1.45; 95%CI: 1.13-
1.87, P=0.004, respectively) (Table 2).
Mortality
During follow up, 257 of 631 patients died. The main
causes of death were recurrence of the original disease,
infection, and GvHD (Table 3).
Discussion
This retrospective analysis of HSCT in CBF AML in sec-
ond hematologic CR was based on a large number of
patients reported to the EBMT. Chemotherapy alone after
relapse in patients with favorable risk AML is able to pro-
duce 5-year survival in 42-44% of patients.16,17 Allogeneic
HSCT is recommended by leading organizations in
Europe and the USA as consolidation treatment for AML
patients achieving CR2.18 In our study, the results of trans-
plantation in terms of OS and LFS were a little worse than
those described previously for patients with CBF AML
transplanted in CR1 and comparable with published out-
comes of HSCT performed in CR2.19,20 Similarly to those
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Figure 2. Leukemia-free survival (LFS), overall survival (OS), and relapse inci-
dence (RI) in patients with core-binding factor acute myeloid leukemia in
patients without versus with molecular remission pre-transplant. 2-year proba-
bility of LFS: 49% (95%CI: 39.8-58.2) vs. 61.6% (95%CI: 56.3-66.9), P=0.046.
2-year probability of OS: 59.9% (95%CI: 50.8-68.9) vs. 65.8% (95%CI: 60.7-71),
P=0.47. 2-year risk of relapse: 29.3% (95%CI: 21.2-37.8) vs. 16.2% (95%CI:
12.4-20.4), P=0.003.
Table 3. Mortality during follow up.
Causes of death                                                           Number
Total                                                                                                  257
Original disease                                                                             83
Infection                                                                                           62
Graft-versus-host disease                                                            59
Other related to transplantation                                                21
Interstitial pneumonitis                                                                9
Sinusoidal obstruction syndrome                                               5
Hemorrhage                                                                                     4
Second malignancy                                                                         4
Cardiac toxicity                                                                                2
Missing                                                                                              8
studies, in our group, patients with inv(16) had a higher
probability of LFS, OS, and a lower risk of relapse than
those with t(8;21). Interestingly, these end points reported
in most papers for patients treated with chemotherapy
alone are not usually different for inv(16) and t(8;21) AML.
On the other hand, the MD Anderson study, for example,
pointed out that patients diagnosed with t(8;21) have a
worse prognosis than those with inv(16).5
Response to chemotherapy with clearance of RUNX1-
RUNX1T1 and CBFB-MYH11 evaluated with RT-qPCR, as
well as additional molecular aberrations detected at diag-
nosis, but not type of CBF AML per se, are most frequently
emphasized as the factors determining outcome in
chemotherapy-treated patients.9,21,22 Presence of MRD
assessed with flow cytometry in AML before transplanta-
tion is a recognized risk factor for inferior outcome.23
Molecular evaluation of MRD in CBF AML before trans-
plantation has not been extensively studied to date. In our
cohort, MRDneg patients had a significantly decreased
risk of relapse compared with MRDpos patients
(HR=0.65, P=0.043); this translated into a trend for
improved LFS (HR=0.76, P=0.08) and GRFS (HR=0.77,
P=0.054) but showed no significant influence on OS
(P=0.47). Data analysis revealed that MRDpos patients
more frequently received donor lymphocyte infusions or
subsequent transplants after relapse than MRDneg
patients. Those therapeutic interventions, and probably
lack of statistical power, may explain why we did not find
a significant difference in OS in favor of MRDneg patients.
The results of our study indicate that even patients who
are MDRpos can expect survival advantage from trans-
plantation compared to those who are treated with
chemotherapy alone.9 A recent paper showed that evalua-
tion of RUNX1-RUNX1T1 was useful to predict relapse
not only before but also after HSCT.24 It should be empha-
sized that the kinetics of relapse in inv(16) and t(8;21)
patients differ, and the latter group requires more frequent
molecular testing.25
According to the 2017 European Leukemia Net and
National Comprehensive Cancer Network guidelines,
additional cytogenetic aberrations in CBF AML do not
modify disease  risk.4,26 In our study group, the presence of
concurrent three or more chromosomal abnormalities had
a marked deleterious effect on relapse (HR=2.31,
P=0.011), LFS (HR=2.09, P=0.004), and even OS (HR=1.68,
P=0.037) after HSCT. Indeed, earlier reports documented
worse outcomes in newly diagnosed CBF AML patients
with three or more cytogenetic abnormalities.5 This find-
ing  may indicate a more complex clonal evolution, and
could support the adoption of anticipated measures to
avoid relapse, such as indication of transplantation in first
remission. 
Not surprisingly, in our study, performance status was a
strong independent risk factor for NRM, LFS, and OS.
Thus, patients with KPS ≥80 had decreased NRM and
improved LFS and OS, which was similar to the findings
of previous studies.27
The intensity of conditioning regimen in the current
analysis favored MAC over RIC in terms of relapse.
Comparable findings were described in a recent EBMT
ALWP study in patients transplanted for secondary AML
with additional benefit of higher probability of LFS and
OS in individuals receiving MAC.28 The results of an
American phase III prospective randomized trial of MAC
versus RIC in AML and myelodysplastic syndrome
patients published in 2017 also revealed statistically higher
relapse rates and worse LFS with a trend for decreased OS
after RIC.29 In contrast, in a German randomized study
including AML patients published a few years earlier, RIC
and MAC yielded identical results for both types of con-
ditioning, even in terms of disease recurrence.30 In our
cohort, conditioning intensity had no significant impact
on LFS or OS. In the German trial, MAC was also a pre-
dictor for aGvHD. Similarly, in our study, MAC was the
only independent risk factor for clinically significant,
grade II-IV aGvHD. The same correlation had been
described previously, and is supported by the concept of a
more pronounced inflammatory reaction after MAC.31
Independent factors influencing cGvHD in our study
were: in vivo TCD, the use of PBSC versus BM, and trans-
plantation from CMV seropositive donors; these findings
are in agreement with previous literature.32,33 Only recent-
ly, possible mechanisms linking CMV immunity and
cGvHD were studied in HSCT recipients. In patients with
cGvHD, a higher proportion of donor-origin high-affinity
CMV-specific cytotoxic T lymphocytes was demonstrat-
ed.34 The composite end point described as GRFS repre-
sents the most desirable outcome of HSCT. In our study,
2- and 5-year probabilities of GRFS were 40.2% and
34.6%, respectively. Recently, a large analysis of 5,059
AML patients from the EBMT database defined transplan-
tation from unrelated donors, PB stem cell transplants, and
unfavorable cytogenetics as prognostic factors for worse
GRFS. In contrast, in vivo TCD was associated with better
results and was the main beneficial factor for GRFS.35 In
our cohort, type of donor and source of stem cells did not
have a significant impact on GRFS, which may be due to
a considerably smaller study sample. Adverse cytogenetics
decreased, while in vivo TCD increased the probability of
GRFS in our patients, which is in line with the results of
the above-mentioned study. 
Our registry-based, retrospective study has various
well-known limitations. For example, due to low report-
ing, we were not able to investigate the prognostic impact
of additional genetic co-mutations frequently observed in
CBF-AML, such as mutations in signaling pathways KIT,
NRAS, KRAS and FLT3.36
The most important findings of our study show that
HSCT in CBF AML in CR2 was able to cure a large pro-
portion of patients, with 2-year and 5-year OS 65% and
58.2%, respectively. The survival of patients with inv(16)
was better than those with t(8;21); an observation which
confirms a substantial underlying difference between the
two CBF AML subtypes also in the transplant setting.
Based on our results, CBF AML patients should receive
MAC rather than RIC, if eligible. Although patients who
were MRDneg had lower risk of relapse and higher prob-
ability of survival without recurrence of leukemia, a signif-
icant proportion of  MRDpos patients obtained durable
response following HSCT. In view of our study, lack of
MRD clearance should not be considered a contraindica-
tion for allogeneic transplantation. 
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